Papers: 24 Sep 2012 - 1 Oct 2012

Check out this week's papers from PubMed. If you are a member, please log in to recommend and comment on papers. If you are not a member, please register today and join the conversation.

Editors' Pick

Subcortical atrophy and cognition: Sex effects in multiple sclerosis.

Schoonheim MM, Popescu V, Rueda Lopes FC, Wiebenga OT, Vrenken H, Douw L, Polman CH, Geurts JJG, Barkhof F

Neurology. 2012 Sep 26. PMID: 23019265. Abstract

Editors' Pick

Expression and activation by epstein barr virus of human endogenous retroviruses-w in blood cells and astrocytes: inference for multiple sclerosis.

Mameli G, Poddighe L, Mei A, Uleri E, Sotgiu S, Serra C, Manetti R, Dolei A

PLoS One. 2012; 7(9):e44991. Epub 2012 Sep 27. PMID: 23028727. Abstract

Editors' Pick

Cross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis Optica.

Ren Z, Wang Y, Duan T, Patel J, Liggett T, Loda E, Brahma S, Goswami R, Grouse C, Byrne R, et al.

J Immunol. 2012 Sep 24. PMID: 23008451. Abstract

Editors' Pick

Design and screening of a glial cell-specific, cell penetrating Peptide for therapeutic applications in multiple sclerosis.

Heffernan C, Sumer H, Guillemin GJ, Manuelpillai U, Verma PJ

PLoS One. 2012; 7(9):e45501. Epub 2012 Sep 25. PMID: 23049807. Abstract

Editors' Pick

Epstein-Barr virus Peptide Presented by HLA-E is Predominantly Recognized by CD8(bright) Cells in multiple Sclerosis Patients.

Jørgensen PB, Livbjerg AH, Hansen HJ, Petersen T, Höllsberg P

PLoS One. 2012; 7(9):e46120. Epub 2012 Sep 25. PMID: 23049954. Abstract

Papers: 17 Sep 2012 - 24 Sep 2012

Check out this week's papers from PubMed. If you are a member, please log in to recommend and comment on papers. If you are not a member, please register today and join the conversation.

Dimethyl Fumarate Shows Efficacy in Phase III Clinical Studies

Experimental oral drug tolerated relatively well

The first peer-reviewed phase III clinical trials of an experimental oral drug for the most common form...

Clinical Research, Drug Development

Editors' Pick

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Fox RJ, Miller DH, Phillips TJ, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, et al.

N Engl J Med. 2012 Sep 20; 367(12):1087-97. Epub 1969 Dec 31. PMID: 22992072. Abstract

Editors' Pick

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, et al.

N Engl J Med. 2012 Sep 20; 367(12):1098-107. Epub 1969 Dec 31. PMID: 22992073. Abstract

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

User Top Menu

Papers: 24 Sep 2012 - 1 Oct 2012

Papers: 17 Sep 2012 - 24 Sep 2012

Dimethyl Fumarate Shows Efficacy in Phase III Clinical Studies

Pages

MSDF Footer

Search form

Papers: 24 Sep 2012 - 1 Oct 2012

Papers: 17 Sep 2012 - 24 Sep 2012

Pages